170 NMS-E628, a potent and orally available small molecule inhibitor of anaplastic lymphoma kinase, reduces tumor growth in an intracranial model of ALK-dependent NSCLC

Elena Ardini(Nerviano Medical Sciences), Arturo Galvani(Nerviano Medical Sciences), Paola Magnaghi(Nerviano Medical Sciences), Paolo Orsini(Nerviano Medical Sciences), Maria Menichincheri(Nerviano Medical Sciences), Cristina Ponti(University of Milan), A. Degrassi, Mariangela Russo(Candiolo Cancer Institute), Enrico Pesenti, Nadia Amboldi(University of Pavia)
European Journal of Cancer Supplements
November 1, 2010
10.1016/s1359-6349(10)71875-9
Cited by 0

Related Papers

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
NK Cells and Cancer
|The Journal of Immunology|2007|296
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
|Molecular Oncology|2014|156
Identification of <i>N</i>,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor
|Journal of Medicinal Chemistry|2009|128